{"version":"1.0","type":"link","title":"Pneumonitis risk from pembrolizumab in non-small cell lung cancer: Interstitial abnormalities matter, and so does treatment.","author_name":"Yamakawa H 외","author_url":"https://prs-insight.online/author/Yamakawa%20H","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/94247","thumbnail_width":1200,"thumbnail_height":630}